Dr. Taylor is the Chief Scientific Officer at Arvinas. He came to the Company after nearly 10 years at Pfizer Oncology, most recently as an Early Development Team Leader. In this role, Dr. Taylor was responsible for leading a cross-functional drug development team that conducted Phase 1 and Phase 2 clinical trials for multiple assets in several cancer indications. His initial role at Pfizer Oncology was as Senior Director of Translational Oncology. In this role, he was responsible for directing translational science activities, which included designing and executing translational research plans and leading companion diagnostic partnerships for programs in both preclinical and clinical (Phase 1 -3) stages.
Prior to Pfizer, Dr. Taylor worked at Bayer Healthcare, Pharmaceuticals, holding positions of increasing responsibility, including Vice President of Cancer Biology. In this position, he led the department responsible for all biology aspects of small molecule drug discovery of cancer therapeutics in the mechanistic areas of signal transduction, cell cycle regulation, angiogenesis and apoptosis. During his tenure, the Cancer Biology group delivered numerous molecules to the Development organization. He also started and led the Biomarker group, which contributed to the development of sorafenib.
Dr. Taylor earned his B.A. from Bowdoin College and his Ph.D. in Molecular Biology and Genetics from Harvard University. He also completed his postdoctoral training in the laboratory of Dr. Harold Varmus at the University of California, San Francisco and the National Institutes of Health (NIH).
What is Ian Taylor's net worth?
The estimated net worth of Ian Taylor is at least $1.73 million as of February 24th, 2025. Dr. Taylor owns 159,121 shares of Arvinas stock worth more than $1,726,463 as of April 5th. This net worth approximation does not reflect any other investments that Dr. Taylor may own. Learn More about Ian Taylor's net worth.
How do I contact Ian Taylor?
Has Ian Taylor been buying or selling shares of Arvinas?
Ian Taylor has not been actively trading shares of Arvinas during the past quarter. Most recently, Ian Taylor sold 9,020 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a transaction totalling $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares of the company's stock, valued at $2,658,911.91. Learn More on Ian Taylor's trading history.
Who are Arvinas' active insiders?
Arvinas' insider roster includes Noah Berkowitz (Chief Medical Officer), Sean Cassidy (CFO), John Houston (CEO), David Loomis (CAO), Bradley Margus (Director), Briggs Morrison (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Andrew Saik (Chief Financial Officer and Treasurer), Timothy Shannon (Director), Ian Taylor (Insider), and Randy Teel (CEO). Learn More on Arvinas' active insiders.
Are insiders buying or selling shares of Arvinas?
In the last year, Arvinas insiders bought shares 2 times. They purchased a total of 50,000 shares worth more than $495,100.00. In the last year, insiders at the sold shares 10 times. They sold a total of 69,794 shares worth more than $848,094.43. The most recent insider tranaction occured on March, 18th when insider Noah Berkowitz sold 6,435 shares worth more than $71,428.50. Insiders at Arvinas own 4.7% of the company.
Learn More about insider trades at Arvinas. Information on this page was last updated on 3/18/2026.
